12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pimavanserin: Completed Phase III enrollment

Acadia completed enrollment of 198 patients in the double-blind, placebo-controlled, North American Phase III (-020 Study) trial evaluating once-daily 40 mg oral pimavanserin for 6 weeks as adjunct to...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >